Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01929941
Recruitment Status : Terminated (Business decision.)
First Posted : August 28, 2013
Last Update Posted : January 17, 2018
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Tracking Information
First Submitted Date  ICMJE August 22, 2013
First Posted Date  ICMJE August 28, 2013
Last Update Posted Date January 17, 2018
Study Start Date  ICMJE September 2013
Actual Primary Completion Date August 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 11, 2014)
  • Adverse events that are defined as dose limiting toxicities occurring in the first 21 days of treatment in Group 1 and the first 28 days of treatment in Group 2. [ Time Frame: Approximately 21 days (Group 1); Approximately 28 days (Group 2) ]
  • Safety and tolerability of INCB047986 monotherapy and in combination with gemcitabine and nab-paclitaxel as assessed by summary of clinical laboratory assessments, Electrocardiogram (ECG), and Adverse Events (AEs). [ Time Frame: Group 1 and Group 2: up to 6 months ]
    Group 1: Baseline and weekly for Cycle 1 and then Day 1 for all subsequent cycles until the End of Treatment visit. Group 2: Baseline and weekly for Cycle 1 and then Day 1, Week 8 and Week 15 for all subsequent cycles until the End of Treatment visit.
Original Primary Outcome Measures  ICMJE
 (submitted: August 27, 2013)
Adverse events that are defined as dose limiting toxicities occurring in the first 21 days of treatment [ Time Frame: Approximately 21 days ]
Subjects will be assigned into cohorts, starting with 6 mg QD and escalating or de-escalating according to protocol criteria
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 11, 2014)
  • Tumor response rates will be derived from investigator assessment of response in subjects with measurable disease [ Time Frame: Approximately 6 months ]
  • Plasma concentrations will be used to estimate peak plasma concentration (cmax) and area under the plasma concentration curve (AUC) [ Time Frame: Day 15 of treatment at a given dose ]
  • Duration of Response (DOR) and Progression Free Survival (PFS) in subjects with measureable disease [ Time Frame: Approximately 6 months ]
  • Plasma concentration of biomarkers and cytokines before and during treatment [ Time Frame: Approximately 6 months ]
  • Change in body weight [ Time Frame: Approximately 6 months ]
  • Change in Eastern Cooperative Oncology Group (ECOG) status from baseline to each visit where the variable is measured [ Time Frame: Approximately 6 months ]
Original Secondary Outcome Measures  ICMJE
 (submitted: August 27, 2013)
  • Tumor response rates will be derived from investigator assessment of response in subjects with measurable disease [ Time Frame: Approximately 6 months ]
  • Plasma concentrations will be used to estimate peak plasma concentration (cmax) and area under the plasma concentration curve (AUC) [ Time Frame: Day 15 of treatment at a given dose ]
  • Duration of Response (DOR) and Progression Free Survival (PFS) in subjects with measureable disease [ Time Frame: Approximately 6 months ]
  • Plasma concentration of biomarkers and cytokines before and during treatment [ Time Frame: Approximately 6 months ]
  • Change in body weight [ Time Frame: Approximately 6 months ]
  • Change in ECOG status from baseline to each visit where the variable is measured [ Time Frame: Approximately 6 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Official Title  ICMJE A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Brief Summary

This is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of INCB047986 and to determine the maximum tolerated dose of INCB047986 in combination with gemcitabine and nab paclitaxel in a select group of patients with solid tumors. Each patient group will participate in a phase of the study which is divided into two parts. The patient groups will be enrolled in a sequential manner starting with Patient Group 1.

Patient Group 1

Group 1 will be comprised of patients with advanced malignancies who will receive INCB047986 as monotherapy.

Part 1: Dose Escalation Phase - This phase will evaluate the safety, tolerability and pharmacokinetics (PK) of INCB047986 when given as described to patients with advanced malignancies. A goal of Part 1 will be to identify the maximally tolerated dose (MTD) of INCB047986 and/or other dose(s) that are tolerated doses and produce a substantial pharmacologic effect. These doses will be used in Part 2 of the study.

Part 2: Expansion Phase - This phase will further explore the safety, tolerability, PK, and preliminary clinical activity of INCB047986 using the doses identified in Part 1.

Group 2

Group 2 will be in subjects with advanced or metastatic pancreatic cancer, breast cancer or urothelial cancer.

Part 1: Dose Optimization Phase - This phase will identify the MTD of INCB047986 in combination with gemcitabine and nab-paclitaxel in patients with advanced or metastatic solid tumors. Specifically, these will be patients with pancreatic adenocarcinoma (first or second line), triple-negative breast cancer (second line) or urothelial cancer (second line).

Part 2: Expansion Phase - This phase will explore the safety, tolerability, PK, biomarkers, and preliminary clinical activity of the dose regimen(s) identified in Part 1. Patients enrolled in this phase will be limited to those with advanced or metastatic pancreatic cancer.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Solid Tumor
  • Hodgkin's Lymphoma
  • NHL (Non-Hodgkin Lymphoma)
  • Pancreatic Cancer
  • Breast Cancer
  • UC (Ureter and Urethera)
  • Advanced Cancer
  • Metastatic Cancer
Intervention  ICMJE
  • Drug: INCB047986
    Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
  • Drug: INCB047986
    INCB047986 tablets administered orally at the protocol specified dose and frequency
  • Drug: Gemcitabine
    Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
    Other Name: Gemzar®
  • Drug: nab-paclitaxel
    nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
    Other Name: Abraxane®
Study Arms  ICMJE
  • Experimental: Group 1 INCB047986
    Intervention: Drug: INCB047986
  • Experimental: Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel
    Interventions:
    • Drug: INCB047986
    • Drug: Gemcitabine
    • Drug: nab-paclitaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: February 3, 2015)
5
Original Estimated Enrollment  ICMJE
 (submitted: August 27, 2013)
60
Actual Study Completion Date  ICMJE August 2014
Actual Primary Completion Date August 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Group 1

  • Aged 18 years or older, with histologically or cytologically confirmed solid tumor, Hodgkin's lymphoma, aggressive or indolent non-Hodgkin's lymphoma. (NOTE: Patients with acute and chronic leukemia, Burkitt's lymphoma, precursor B lymphoblastic leukemia/lymphoma, and myeloma are excluded)
  • Life expectancy of 12 weeks or longer.
  • Subject must have received ≥ 1 prior treatment regimen.
  • The subject must not be a candidate for potentially curative therapy, including transplant.

Group 2

  • Aged 18 years or older
  • Part 1 - Histologically or cytologically confirmed pancreatic adenocarcinoma (first or second line), triple-negative breast cancer (second line), or urothelial cancer (second line)
  • Part 2 - Histologically or cytologically confirmed pancreatic adenocarcinoma
  • No more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy).
  • There is no restriction on the number of prior non-myelosuppressive targeted therapies or hormonal agents (e.g., epidermal growth factor receptor-targeted therapy for lung cancer and hormonal therapy for breast cancer or ovarian cancer); NOTE: Targeted and/or hormonal therapy alone will not be considered chemotherapy for the purposes of this study.

Exclusion Criteria:

Group 1 and 2

  • Received an investigational study drug within 28 days or 5 half-lives (whichever is longer) prior to receiving their first dose of study drug.
  • Received any approved anticancer medications within 21 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug (42 days for nitrosoureas) EXCEPT steroids at ≤ 10 mg prednisone daily (or equivalent).
  • Has any unresolved toxicity ≥ Grade 2 from previous anticancer therapy without medical monitor approval.

    o Subjects with ongoing chronic toxicities such as fatigue or neuropathy may be allowed after approval from the sponsor's medical monitor

  • Evidence of uncontrolled brain metastases or history of spinal cord compression, or primary central nervous system (CNS) tumors.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 2.
  • Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or is currently receiving immunosuppressive therapy following allogeneic transplant.
  • Received autologous hematopoietic stem cell transplant within the last 3 months.
  • Radiation treatment within the previous 4 weeks.
  • History of active hepatitis or positive serology for hepatitis B (unless due to vaccination) or C
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries Canada
 
Administrative Information
NCT Number  ICMJE NCT01929941
Other Study ID Numbers  ICMJE INCB 47986-103
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Incyte Corporation
Study Sponsor  ICMJE Incyte Corporation
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: William Williams, M.D. Incyte Corporation
PRS Account Incyte Corporation
Verification Date January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP